Isotretinoin and timing of procedural interventions: Clinical implications and practical points.

Background: For decades, the notion that elective surgeries and cutaneous procedures should be postponed for 6-12 months in patients on, or recently administered with isotretinoin, has been widely accepted. However, some recent studies showed the need for a change in this regard.

Method: Here, we reviewed the existing data in this regard through searching on PubMed, Google Scholar, and Scopus.

Serious health threat of mucormycosis during the ongoing COVID-19 pandemic: what dermatologists need to know in this regard.

Background: Recently, a surge of mucormycosis in patients affected with or recovered from SARS-Cov-2 has been noted, especially in developing countries such as India, Pakistan, and Iran.

Aim: To focus on existing data about the important aspects of COVID-associated mucormycosis.

Methods: We searched on PubMed, Google Scholar, and Scopus in this regard, and all of the relevant papers published until August 28, 2021, for which we could access their full-texts, were included.

COVID vaccination in patients under treatment with rituximab: A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus.

SARS-COV2 vaccines were approved without long-term monitoring due to emergent situations. This has raised some issues about the timing and protocol of receiving vaccines in specific situations such as patients receiving immunomodulatory agents including rituximab, which is widely used for various disorders such as multiple sclerosis, pemphigus, and many rheumatologic disorders. We described two cases of pemphigus vulgaris (a new case and one with flare-up) following vaccination with Astrazeneca in Iran and reviewed the existing data in this regard through searching on PubMed, Google Scholar, and Scopus.